Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (vol 378, pg 1931, 2011)

被引：0
|
作者：
Rini, B., I
Escudier, B.
Tomczak, P.
机构：
来源：
LANCET | 2012年 / 380卷 / 9856期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1818 / 1818
页数：1
相关论文
共 50 条
  • [21] Axitinib in advanced renal-cell carcinoma (vol 14, pg 1245, 2013)
    Yousaf, N.
    Larkin, J.
    LANCET ONCOLOGY, 2014, 15 (03): : E106 - E106
  • [22] Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of secondline axitinib versus sorafenib in metastatic renal cell carcinoma.
    Escudier, Bernard J.
    Rini, Brian I.
    Motzer, Robert J.
    Tarazi, Jamal Christo
    Kim, Sinil
    Huang, Xin
    Rosbrook, Brad
    English, Patricia A.
    Loomis, A. Katrina
    Williams, James Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
    Cella, D.
    Escudier, B.
    Rini, B. I.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
    Larkin, J. M. G.
    Ferguson, T. R.
    Pickering, L. M.
    Edmonds, K.
    James, M. G.
    Thomas, K.
    Banerji, U.
    Berns, B.
    de Boer, C.
    Gore, M. E.
    BRITISH JOURNAL OF CANCER, 2010, 103 (08) : 1149 - 1153
  • [25] A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
    J M G Larkin
    T R Ferguson
    L M Pickering
    K Edmonds
    M G James
    K Thomas
    U Banerji
    B Berns
    C de Boer
    M E Gore
    British Journal of Cancer, 2010, 103 : 1149 - 1153
  • [26] Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial
    Hutson, Thomas E.
    Al-Shukri, Salman
    Stus, Viktor P.
    Lipatov, Oleg N.
    Shparyk, Yaroslav
    Bair, Angel H.
    Rosbrook, Brad
    Andrews, Glen I.
    Vogelzang, Nicholas J.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (01) : 72 - 76
  • [27] DETAILED COMPARISON OF THE SAFETY OF TIVOZANIB VERSUS SORAFENIB IN PATIENTS WITH ADVANCED/METASTATIC RENAL CELL CARCINOMA (MRCC) FROM A PHASE 3 TRIAL
    Eisen, T. Q. G.
    Sternberg, C. N.
    Tomczak, P.
    Harza, M.
    Jinga, V.
    Esteves, B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 262 - 263
  • [28] Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Wang, Hai
    Man, Libo
    Li, Guizhong
    Huang, Guanglin
    Wang, Jianwei
    ONCOTARGETS AND THERAPY, 2016, 9 : 3423 - 3432
  • [29] Cost effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada
    Jaszewski, B.
    Gao, X.
    Reddy, P.
    Bhardwaj, T.
    Bjarnason, G.
    Finelli, A.
    Kapoor, A.
    Abugaber, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] PROGRESSION FREE SURVIVAL VS OVERALL SURVIVAL: AN EXAMPLE FROM RANDOMISED PHASE III TRIAL WITH AXITINIB (AXIS) IN METASTATIC RENAL CELL CARCINOMA
    Alam, Mahmood
    Delahoy, Philippa
    Park, Simon H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 306 - 306
12345